Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old

JAMA

Volumn 296, Issue 16, 2006, Pages 1990-1997

  Hambidge, Simon J ^a,b,c   Glanz, Jason M ^a,c   France, Eric K ^a,c   McClure, David ^a   Xu, Stanley ^a   Yamasaki, Kristi ^a   Jackson, Lisa ^d   Mullooly, John P ^e   Zangwill, Kenneth M ^f   Marcy, S Michael ^g   Black, Steven B ^g   Lewis, Edwin M ^g   Shinefield, Henry R ^h   Belongia, Edward ⁱ   Nordin, James ^j   Chen, Robert T ^k   Shay, David K ^k   Davis, Robert L ^k   DeStefano, Frank ^k  

^a CLINICAL RESEARCH UNIT   (United States)

^b Children's Hospital Colorado   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g KAISER PERMANENTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MARSHFIELD CLINIC   (United States)

^j HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^k CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; TRIPLE VACCINE;

ANEMIA; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BRAIN INJURY; BRONCHIOLITIS; BRONCHUS DISEASE; CELLULITIS; CERUMEN IMPACTION; CONTROLLED STUDY; CONVULSION; COUGHING; DERMATITIS; DRUG SAFETY; DUODENITIS; DYSPNEA; ENTERITIS; FEBRILE CONVULSION; GASTRITIS; GASTROENTERITIS; HUMAN; INFANT; INFLUENZA; LYMPHADENITIS; MAJOR CLINICAL STUDY; OTITIS MEDIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SICKLE CELL ANEMIA; TRACHEA DISEASE; URTICARIA;

EID: 33750318163     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.16.1990     Document Type: Article

References (40)

1. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232-239.
2. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225-231.
3. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis. 1987;136:550-555.
4. Rennels MB, Meissner HC; Committee on Infectious Diseases, American Academy of Pediatrics. Technical report: reduction of the influenza burden in children. Pediatrics. 2002;110:6 http://www.pediatrics.org/cgi/content/full/110/ 6/e80. Accessed October 1, 2006.
5. Grijalva CG, Craig AS, Dupont WD, et al. Estimating influenza hospitalizations among children. Emerg Infect Dis. 2006;12:103-109.
6. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355:31-40.
7. Harper SA, Fukuda K, Uyeki TM; Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2004;53(RR-6):1-40.
8. Centers for Disease Control and Prevention. Estimated influenza vaccination coverage among adults and children-United States, September 1, 2004-January 31, 2005. MMWR Recomm Rep. 2005;54:304-307.
9. Bernstein DI, Zahradnik JM, DeAngelis CJ, Cherry JD. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics. 1982;69:404-408.
10. American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med. 2001;345:1529-1536.
11. Groothuis JR, Levin MJ, Rabalais GP, Meiklejohn G, Lauer BA. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics. 1991;87:823-828.
12. Piedra PA, Glezen WP, Mbawuike I, et al. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine. 1993;11:718-724.
13. Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J. 2004;23:189-200.
14. France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med. 2004;158:1031-1036.
15. Skowronski DM, Jacobsen K, Daigneault J, et al. Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts. Pediatrics. 2006;117:1963-1971.
16. Ropper AH, Victor M. Influenza vaccine and the Guillain-Barre' Syndrome. N Engl J Med. 1998;339:1845-1846.
17. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré Syndrome following influenza vaccination. JAMA. 2004;292:2478-2481.
18. Scheifele DW, Duval B, Russell ML, et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clin Infect Dis. 2003;36:850-857.
19. Goodman MJ, Nordin JD, Harper P, DeFor T, Zhou XZ. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age. Pediatrics. 2006;117:e821-e826.
20. Maclure M. The case-crossover design: a method for studying transient effects on risk of acute events. Am J Epidemiol. 1991;133:144-153.
21. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51:228-235.
22. Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine. 2004;22:2064-2070.
23. Whitaker HJ, Farrington CP, Musonda P. Tutorial in biostatisitcs: the self-controlled case series method. Stat Med. 2006;25:1768-1797.
24. Glanz JM, McClure DL, Xu S, et al. Four different study designs to evaluate vaccine safety were equally valid with contrasting limitations. J Clin Epidemiol. 2006;59:808-818.
25. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States: the Vaccine Safety Datalink Team. Pediatrics. 1997;99:765-773.
26. Tata LJ, West J, Harrison T, Farrington CP, Smith C, Hubbard R. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax. 2003;58:835-839.
27. Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics. 2000;106:e62.
28. Liang KY. Extended Mantel-Haenszel estimating procedure for multivariate logistic regressions. Biometrics. 1987;43:289-300.
29. Finkelstein JA, Davis RL, Dowell SF, et al. Reducing antibiotic use in children: a randomized trial in 12 practices. Pediatrics. 2001;108:1-7.
30. McMahon AW, Iskander J, Haber P, et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. Pediatrics. 2005;115:453-460.
31. Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001;345:656-661.
32. Orr P; Health Canada; National Advisory Committee on Immunization (NACI). Supplementary statement for the 2002-2003 influenza season: update on oculo-respiratory syndrome in association with influenza vaccination. Can Commun Dis Rep. 2002;28(ACS-6):1.
33. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine: a double-blind placebo-controlled trial in twins. Lancet. 1986;1:939-942.
34. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004;23:138-144.
35. Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005;116:e397-e407 www.pediatrics.org/cgi/doi/10.1542/peds.2004- 2258. Accessed October 1, 2006.
36. Fine PE. Non-specific "non-effects" of vaccination. BMJ. 2004;329:1297-1298.
37. Kramarz P, DeStefano F, Gargiullo PM, et al. Does influenza vaccination prevent asthma exacerbations in children? J Pediatr. 2001;138:306-310.
38. Mullooly JP, Crane B, Chun C. Trivalent inactivated influenza vaccine safety in children: assessing the contribution of telephone encounters. Vaccine. 2006;24:2256-2263.
39. Wright PF, Sell SH, Thompson J, Karzon DT. Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants. J Pediatr. 1976;88:31-35.
40. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA; Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006;55(RR-10):1-42.